Date 7th April 2023
Celix Pharma announces the launch of Sitagliptin + Metformin tablets.
Celix Pharma is pleased to announce the launch of Sitagliptin/Metformin 50mg/1000mg film-coated tablets on loss of exclusivity in the UK. Sitagliptin/Metformin are supplied in blister (patient) packs containing 56 tablets.
Sitagliptin/Metformin is indicated for type 2 diabetes in adult patients as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin and/or a sulphonylurea. Sitagliptin works by increasing the amount of insulin that the body makes, which is the hormone that controls sugar levels in your blood1. Metformin works by helping to restore body's proper response to the insulin that one naturally produces2.
Commenting on this launch, Subir Kohli, Co-founder & CEO said, “Another Day 1 launch for Celix Pharma, adding to our established franchise of Sitagliptin (mono) on the UK market.”
Shantreddy, Co-founder & COO added, “Extremely pleased with another patent-expiry linked launch. This is Celix Pharma’s 7th Product launch and one of several launches planned in 2023.”
Source:
1 NHS UK (https://www.nhs.uk/medicines/sitagliptin/about-sitagliptin/)
2 https://www.webmd.com/drugs/2/drug-148074/janumet-oral/details